scholarly journals Psychopathological disorders in chronic cerebral ischemia: possibilities of prevention

2021 ◽  
Author(s):  
О.В. Котова ◽  
Н.Л. Зуйкова ◽  
А.В. Палин ◽  
В.И. Фролова ◽  
Е.В. Гушанская ◽  
...  
Keyword(s):  
Cerebral Ischemia ◽  
Somatoform Disorders ◽  
Professional Activity ◽  
Chronic Cerebral Ischemia ◽  
Dyscirculatory Encephalopathy ◽  
General Weakness ◽  
Combined Use ◽  
Wide Range ◽  
Psychopathological Disorders ◽  
Anxiety Depression

Одними из наиболее важных для уровня социального функционирования и адаптации составляющих клинической картины хронической ишемии мозга (дисциркуляторная энцефалопатия, болезнь малых сосудов) являются психопатологические симптомокомплексы: тревожные, смешанные тревожно-депрессивные, органоневротические (соматоформные), нозогенные расстройства, расстройства приспособительных реакций, неврастения, соматогенная астения. Раннее начало терапии хронической ишемии мозга (ХИМ) является важной задачей по предупреждению прогрессирования не только церебрально-сосудистой патологии, но и широкого круга коморбидных психопатологических расстройств. К пациентам с ХИМ необходим индивидуальный подход с учетом патогенетических факторов и выраженности как когнитивных, так и психопатологических расстройств с привлечением широкого круга средств, включая нейропротекторы. С этой целью в клинической практике используются для самостоятельного или комбинированного применения этилметилоксипиридина сукцинат и цитиколин. На фоне приема этих препаратов пациенты с различными формами ХИМ отмечают субъективное улучшение своего состояния в виде уменьшения утомляемости, общей слабости, эмоциональной лабильности, симптомов психической и соматической тревоги, а также повышения активности и мотивации деятельности, улучшения памяти, внимания и способности концентрироваться, что положительно отражается на их профессиональной деятельности. Anxiety, depression, somatoform disorders, nosogenic reactions, adjustment disorders, neurasthenia, somatogenic asthenia in patient with chronic cerebral ischemia (dyscirculatory encephalopathy, cerebrovascular disease) (CCI) are very important for the level of social functioning and adaptation. Early initiation of CCI therapy is an important task in preventing the progression not only of cerebrovascular pathology, but also a wide range of comorbid psychopathological disorders. Treatment of patients with CCI requires an individual approach taking into account pathogenetic factors and severity of both cognitive and psychopathological disorders. It should involve a wide range of drugs, including neuroprotectors. For this purpose the neuroprotective agents ethylmethyloxypyridine succinate and citicoline can be used for independent or combined use. Patients with various forms of CCI noticed subjective improvement during treatment which includes decreasing fatigability and general weakness, reduction of symptoms of psychic and somatic anxiety, fatigability, emotional lability, increasing activity and motivation, improvement of memory, attention, ability to concentrate that positively influences their professional activity.

scholarly journals Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy)

2019 ◽  
Vol 11 (3S) ◽  
pp. 61-67 ◽  
Author(s):  
V. A. Parfenov
Keyword(s):  
Cognitive Impairment ◽  
Cerebral Ischemia ◽  
Emotional Disorders ◽  
Blood Lipid ◽  
Vascular Cognitive Impairment ◽  
Considerable Proportion ◽  
Secondary Headache ◽  
Chronic Cerebral Ischemia ◽  
Dyscirculatory Encephalopathy ◽  
Blood Clots

The paper reviews the literature on vascular cognitive impairment (VCI), the diagnosis widely used in foreign neurological practice, as well as chronic cerebral ischemia (CCI) and dyscirculatory encephalopathy (DEP), the common diagnoses in Russian neurological practice. According to the etiology, risk factors, and manifestations, Stages I and II DEP largely corresponds to moderate VCI; Stage III DEP does to severe VCI. The results of the author’s studies show that a considerable proportion of patients followed up with a diagnosis of CCI, DEP, have no signs of chronic cerebrovascular disease (CVD), but suffer from primary or secondary headache, vertigo of various origins, emotional disorders, and other diseases. The diagnosis of CCI, DEP should be based on the presence of CCI, the reliable neuroimaging signs of chronic CVD, and the ruling out of other diseases. When treating and preventing VCI, CCI, and DEP, a premium is placed upon both non-drug (regular physical activity, smoking cessation, rational nutrition) and drug therapy aimed at normalizing blood pressure and blood lipid spectrum, preventing blood clots, and improving cognitive functions.

scholarly journals Chronic cerebrovascular diseases: use of vinpocetine in neurological practice (Round Table proceedings)

2018 ◽  
Vol 10 (4) ◽  
pp. 139-145 ◽  
Author(s):  
V. A. Parfenov ◽  
S. A. Zhivolupov ◽  
V. V. Zakharov ◽  
L. A. Belova ◽  
O. V. Lagoda ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cognitive Impairment ◽  
Cerebral Ischemia ◽  
Neurological Diseases ◽  
Round Table ◽  
Vascular Cognitive Impairment ◽  
Cerebrovascular Diseases ◽  
Chronic Cerebral Ischemia ◽  
Dyscirculatory Encephalopathy ◽  
Clinical Presentations

The paper presents the proceedings of the Round Table with the participation of leading neurologists, which is devoted to chronic cerebrovascular diseases. It is noted that chronic cerebral ischemia (CCI), or dyscirculatory encephalopathy (DEP), is one of the most common neurological diagnoses in our country. The pathogenesis, clinical presentations, diagnosis and treatment of CCI (DEP) and its matching with vascular cognitive impairment (CI), which is regarded in foreign literature as the main manifestation of chronic cerebrovascular disease (CVD) were considered. The authors analyze clinical trials evaluating the efficacy of vinpocetine (Cavinton) in chronic CVD, dizziness, CI, as well as the use of new vinpocetine formulations, such as Cavinton Comforte, in various neurological diseases, dysphagia in particular, in poststroke patients.

Stress, anxiety, depression and burnout in frontline health care workers during COVID-19 pandemic: a brief systematic review and new data from Russia

2021 ◽  
Author(s):  
Ekaterina Mosolova ◽  
Dmitry Sosin ◽  
Sergey Mosolov
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Female Gender ◽  
Assessment Tools ◽  
Care Workers ◽  
Younger Age ◽  
Wide Range ◽  
Associated Risk Factors ◽  
Anxiety Depression ◽  
The Impact

During the COVID-19 pandemic, healthcare workers (HCWs) have been subject to increased workload while also exposed to many psychosocial stressors. In a systematic review we analyze the impact that the pandemic has had on HCWs mental state and associated risk factors. Most studies reported high levels of depression and anxiety among HCWs worldwide, however, due to a wide range of assessment tools, cut-off scores, and number of frontline participants in the studies, results were difficult to compare. Our study is based on two online surveys of 2195 HCWs from different regions of Russia during spring and autumn epidemic outbreaks revealed the rates of anxiety, stress, depression, emotional exhaustion and depersonalization and perceived stress as 32.3%, 31.1%, 45.5%, 74.2%, 37.7% ,67.8%, respectively. Moreover, 2.4% of HCWs reported suicidal thoughts. The most common risk factors include: female gender, nurse as an occupation, younger age, working for over 6 months, chronic diseases, smoking, high working demands, lack of personal protective equipment, low salary, lack of social support, isolation from families, the fear of relatives getting infected. These results demonstrate the need for urgent supportive programs for HCWs fighting COVID-19 that fall into higher risk factors groups.

Citimax-Darnitsa in the treatment of patients with chronic cerebral ischemia

2017 ◽  
Vol 0 (1.87) ◽  
pp. 117-122
Author(s):  
O.L. Tovazhnianska ◽  
I.O. Lapshina ◽  
A.H. Chernenko ◽  
O.I. Kauk
Keyword(s):  
Cerebral Ischemia ◽  
Chronic Cerebral Ischemia

scholarly journals Fructose Enhanced Reduction of Bacterial Growth on Nanorough Surfaces

2013 ◽  
Vol 1498 ◽  
pp. 73-78 ◽  
Author(s):  
N. Gozde Durmus ◽  
Erik N. Taylor ◽  
Kim M. Kummer ◽  
Thomas J. Webster
Keyword(s):  
Bacterial Growth ◽  
Biofilm Formation ◽  
Antibacterial Agents ◽  
Bacteria Growth ◽  
Planktonic Bacteria ◽  
Combined Use ◽  
Wide Range ◽  
Metabolic Stimulation ◽  
Antibacterial Surfaces ◽  
First Time

ABSTRACTBiofilms are a major source of medical device-associated infections, due to their persistent growth and antibiotic resistance. Recent studies have shown that engineering surface nanoroughness has great potential to create antibacterial surfaces. In addition, stimulation of bacterial metabolism increases the efficacy of antibacterial agents to eradicate biofilms. In this study, we combined the antibacterial effects of nanorough topographies with metabolic stimulation (i.e., fructose metabolites) to further decrease bacterial growth on polyvinyl chloride (PVC) surfaces, without using antibiotics. We showed for the first time that the presence of fructose on nanorough PVC surfaces decreased planktonic bacteria growth and biofilm formation after 24 hours. Most importantly, a 60% decrease was observed on nanorough PVC surfaces soaked in a 10 mM fructose solution compared to conventional PVC surfaces. In this manner, this study demonstrated that bacteria growth can be significantly decreased through the combined use of fructose and nanorough surfaces and thus should be further studied for a wide range of antibacterial applications.

Cerebral microdialysis monitoring: determination of normal and ischemic cerebral metabolisms in patients with aneurysmal subarachnoid hemorrhage

2000 ◽  
Vol 93 (5) ◽  
pp. 808-814 ◽  
Author(s):  
Mette K. Schulz ◽  
Lars Peter Wang ◽  
Mogens Tange ◽  
Per Bjerre
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Cerebral Ischemia ◽  
Delayed Cerebral Ischemia ◽  
Neuronal Injury ◽  
Low Flow ◽  
Cerebral Microdialysis ◽  
Intracerebral Microdialysis ◽  
Content Type ◽  
Wide Range ◽  
Fine Print

Object. The success of treatment for delayed cerebral ischemia is time dependent, and neuronal monitoring methods that can detect early subclinical levels of cerebral ischemia may improve overall treatment results. Cerebral microdialysis may represent such a method. The authors' goal was to characterize patterns of markers of energy metabolism (glucose, pyruvate, and lactate) and neuronal injury (glutamate and glycerol) in patients with subarachnoid hemorrhage (SAH), in whom ischemia was or was not suspected.Methods. By using low-flow intracerebral microdialysis monitoring, central nervous system extracellular fluid concentrations of glucose, pyruvate, lactate, glutamate, and glycerol were determined in 46 patients suffering from poor-grade SAH. The results in two subgroups were analyzed: those patients with no clinical or radiological signs of cerebral ischemia (14 patients) and those who succumbed to brain death (five patients).Significantly lower levels of energy substrates and significantly higher levels of lactate and neuronal injury markers were observed in patients with severe and complete ischemia when compared with patients without symptoms of ischemia (glucose 0 compared with 2.12 ± 0.15 mmol/L; pyruvate 0 compared with 151 ± 11.5 µmol; lactate 6.57 ± 1.07 compared with 3.06 ± 0.32 mmol/L; glycerol 639 ± 91 compared with 81.6 ± 12.4 µmol; and glutamate 339 ± 53.4 compared with 14 ± 3.33 µmol). Immediately after catheter placement, glutamate concentrations declined over the first 4 to 6 hours to reach stable values. The remaining parameters exhibited stable values after 1 to 2 hours.Conclusions. The results confirm that intracerebral microdialysis monitoring of patients with SAH can be used to detect patterns of cerebral ischemia. The wide range from normal to severe ischemic values calls for additional studies to characterize further incomplete and possible subclinical levels of ischemia.

Clinical and neuroimaging features of chronic cerebral ischemia in polycythemia vera

2021 ◽  
pp. 58-62
Author(s):  
G. V. Zyrina ◽  
T. A. Slyusa
Keyword(s):  
Cerebral Ischemia ◽  
Polycythemia Vera ◽  
Mini Mental State Examination ◽  
Comparison Group ◽  
Cognitive Disorders ◽  
Chronic Cerebral Ischemia ◽  
State Examination ◽  
The Brain

The purpose of the study. To study clinical and neuroimaging features of chronic cerebral ischemia (CCI) in polycythemia vera (PV).Materials and methods. 66 patients with PV were examined – the main group (43 men, 23 women; mean age 62.0 ± 3.4 years), of which 64 (97.0%) patients were diagnosed with CCI. The comparison group consisted of 85 patients with CCI (34 men, 51 women; mean age 67.7 ± 4.6 years), who developed against the background of cerebral vascular atherosclerosis and arterial hypertension. To identify cognitive disorders, we used Mini Mental State Examination (MMSE). Insomnia was studied in accordance with the criteria of the International Classification of Sleep ICDS‑22005. The quality of sleep was determined using a questionnaire from the Federal Somnological Center. Neuroimaging (MRI of the brain) was performed on Siemens Symphony 1.5 T and GE Signa 1.5 T tomographs.Results. Subjective symptoms CCI are characterized by a greater representation of asthenic and insomniac disorders. Transient ischemic attacks in patients with PV are significantly more common than in the comparison group, their frequency depends on the duration of PV. The revealed changes in MRI of the brain in the majority of PV patients with CCI are characteristic of multiinfarction vascular encephalopathy; in the comparison group, changes that characteristic for subcortical arteriosclerotic encephalopathy were more often recorded.

Potential Protective Effect of Dl-3-n-Butylphthalide on Chronic Cerebral Ischemia Brain Injury

2021 ◽  
Vol 21 ◽  
Author(s):  
Fangfang Zhao ◽  
Yumin Luo
Keyword(s):  
Oxidative Stress ◽  
Cerebral Ischemia ◽  
Brain Dysfunction ◽  
Cerebrovascular Diseases ◽  
Pathophysiological Mechanism ◽  
Chronic Cerebral Ischemia ◽  
Celery Seed ◽  
Prevention And Treatment ◽  
Ischemic Cerebrovascular Diseases ◽  
The Common

: Chronic cerebral ischemia is one of the common ischemic cerebrovascular diseases. Chronic cerebral ischemia can lead to brain dysfunction, and its pathophysiological mechanism involves inflammation, blood-brain barrier destruction, oxidative stress, and other factors. Due to it being difficult to detect, it is easily overlooked, and it is often only observed following onset of cognitive dysfunction. At present, there are few drugs for this treatment. DL-3-N-BUTYLPHTHALIDE (NBP), a compound extracted from celery seed, may play an important role in protecting against brain damage caused by chronic cerebral ischemia. Therefore, we pay more attention to the prevention and treatment of NBP on chronic cerebral ischemia.

Sign in / Sign up

Export Citation Format

Share Document